Abstract
Purpose
Cantuzumab mertansine (SB-408075; huC242–DM1) is a conjugate of the maytansinoid drug DM1 to the antibody huC242, which targets CanAg antigen. In previous studies, cantuzumab mertansine was considered safe and tolerable, but transaminitis precluded tolerance of higher doses. Based on those studies, it was suggested that treatment at intervals of the half-life of the intact immunoconjugate may allow a higher dose density. This provided the rationale for the three-times weekly treatment explored in this protocol.
Methods
Patients with advanced solid tumors and documented CanAg expression were treated with escalating doses of cantuzumab mertansine IV administered three-times a week in a 3 out of 4 weeks schedule. Plasma samples were assayed to determine pharmacokinetic parameters.
Results
Twenty patients (pts) with colon (11/20), rectal carcinomas (2/20), or other malignancies (7/20) were treated with doses ranging from 30 to 60 mg/m2 per day of cantuzumab mertansine IV three-times a week. The maximum tolerated dose (MTD) was 45 mg/m2, and the dose-limiting toxicity was grade 3 transaminitis. Hepatic, hematologic, and neurosensory effects occurred, but were rarely severe with repetitive treatment at doses of 45 mg/m2.
Conclusions
Treatment with cantuzumab mertansine at 45 mg/m2 per day three-times weekly × 3-every-4-week schedule proved that a dose-intense treatment with an immunoconjugate can be safely administered. The pharmacokinetic profile of the intact immunoconjugate indicates that the linker is cleaved with a half-life of about 2 days, resulting in faster clearance of the maytansinoid relative to the antibody. Therefore, with the development of second-generation immunoconjugates, there is a need for improvement of the immunoconjugate linker to take full advantage of the slow clearance of full-length antibody molecules.
This is a preview of subscription content, log in via an institution to check access.
References
Ricart AD, Tolcher AW (2007) Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol 4(4):245–255
Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23(9):1137–1146
Parry S, Silverman HS, McDermott K, Willis A, Hollingsworth MA, Harris A (2001) Identification of MUC1 proteolytic cleavage sites in vivo. Biochem Biophys Res Commun 283(3):715–720
Haglund C, Lundin J, Kuusela P, Roberts PJ (1994) CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer 70(3):487–492
Haglund C, Lindgren J, Roberts PJ, Kuusela P, Nordling S (1989) Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Br J Cancer 60(6):845–851
Rao PN, Freireich EJ, Smith ML, Loo TL (1979) Cell cycle phase-specific cytotoxicity of the antitumor agent maytansine. Cancer Res 39(8):3152–3155
Issell BF, Crooke ST (1978) Maytansine. Cancer Treat Rev 5(4):199–207
Smith SV (2004) Technology evaluation: cantuzumab mertansine, ImmunoGen. Curr Opin Mol Ther 6(6):666–674
Lambert J, DeWitte M, Martino HK (2000) SB-408075 investigator brochure. SmithKline Beecham, Collegeville
Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ et al (2006) Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66(6):3214–3221
Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C et al (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 21(2):211–222
Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, Sprague E et al (2004) A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res 10(13):4363–4368
Blum RH, Kahlert T (1978) Maytansine: a phase I study of an ansa macrolide with antitumor activity. Cancer Treat Rep 62(3):435–438
Cabanillas F, Rodriguez V, Hall SW, Burgess MA, Bodey GP, Freireich EJ (1978) Phase I study of maytansine using a 3-day schedule. Cancer Treat Rep 62(3):425–428
Chahinian AP, Nogeire C, Ohnuma T, Greenberg ML, Sivak M, Jaffrey IS et al (1979) Phase I study of weekly maytansine given by iv bolus or 24-hour infusion. Cancer Treat Rep 63(11–12):1953–1960
Franklin R, Samson MK, Fraile RJ, Abu-Zahra H, O’Bryan R, Baker LH (1980) A phase I–II study of maytansine utilizing a weekly schedule. Cancer 46(5):1104–1108
Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K et al (2006) Antibody–maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66(8):4426–4433
Lambert JM, Howard M, Connors K, McCreery H, Rowinsky EK, Tolcher AW (2003) Cantuzumab mertansine (SB-408075), a maytansinoid immunoconjugate directed to the CanAg antigen by the C242 antibody: correlation of the pattern of CanAg expression by immunohistochemistry (IHC) with plasma CEA trends in patients with colorectal cancer in a phase I study. Proc Am Soc Clin Oncol 22 (abstr 1495)
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by GlaxoSmithKline, USA.
The corresponding author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to permit this article (if accepted) to be published in Cancer Chemotherapy and Pharmacology.
Rights and permissions
About this article
Cite this article
Rodon, J., Garrison, M., Hammond, L.A. et al. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemother Pharmacol 62, 911–919 (2008). https://doi.org/10.1007/s00280-007-0672-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-007-0672-8